Sign inJoin waitlistJoin the waitlist

Jessica Gartrell

Assistant Member, St. Jude Faculty · St Jude Children's Research Hospital

Credentials: · ·

History

St Jude Children's Research Hospital
Present

Pediatrics
University of Tennessee College of Medicine
2013–2016
Doctor of Medicine
2009–2013

Research

A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies
European Journal of Cancer · 2020 · 64 citations
Recent advances in understanding and managing pediatric rhabdomyosarcoma
Review · F1000Research · 2020 · First of 2 authors · 37 citations
SLFN11 is Widely Expressed in Pediatric Sarcoma and Induces Variable Sensitization to Replicative Stress Caused By DNA-Damaging Agents
Molecular Cancer Therapeutics · 2021 · First of 21 authors · 17 citations

Alberto Pappo
6 papers
Sara Federico
6 papers
Christopher Tinkle
5 papers
Teresa Santiago
5 papers
Wayne Furman
5 papers
Zachary Abramson
5 papers
Barry Shulkin
4 papers
Robert Ruiz
4 papers
Sara Helmig
4 papers
Andrew Murphy
3 papers
Elizabeth Stewart
3 papers
Larissa Furtado
3 papers

Clinical trials

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
Principal investigator · Recruiting · Phase 1, Phase 2
St. Jude Children's Research Hospital
2024–2037
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
Principal investigator · Recruiting · Phase 1, Phase 2
St. Jude Children's Research Hospital
2022–2037
A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
Site PI · Recruiting · Phase 1
National Cancer Institute (NCI)
2026–2027
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Site PI · Recruiting · Phase 1, Phase 2
Children's Oncology Group
2021–2028